# Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma

> **NCT04995120** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 42 (estimated)

## Conditions studied

- Laryngeal Cancer
- Hypopharynx Cancer
- Laryngeal Neoplasms

## Interventions

- **DRUG:** chemotherapy TP regimen combined with Toripalimab

## Key facts

- **NCT ID:** NCT04995120
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-07
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2022-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04995120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04995120, "Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04995120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*